An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition

Abstract

AIM:To assess the relative bioavailability and pharmacokinetic properties of two formulations (test and reference) of Lafutidine 10 mg. METHODS:The study was performed as an open label, randomized, two-way, two-period, two-treatment, single dose cross-over bioequivalence study, under non-fed condition to compare the pharmacokinetic profiles of the lafutidine formulation manufactured by Emcure Pharmaceuticals Ltd., India using an indigenously developed active pharmaceutical ingredient (API) and the commercially available Stogra ® formulation, of UCB Japan Co., Ltd., Japan. The two treatments were separated by a washout period of 5 d. After an overnight fasting period of 10 h, the subjects were administered either the test or the reference medication as per the randomization schedule. Blood samples were collected at intervals up to 24 h, as per the approved protocol. Concentrations of lafutidine in plasma were analyzed by a validated liquid chromatography/tandem mass spectrometry (LC/MS/MS) method, and a non-compartmental model was used for pharmacokinetic analysis. The pharmacokinetic parameters were subjected to a 4-way ANOVA accounting for sequence, subjects, period and treatment. Statistical significance was evaluated at 95% confidence level (P ≥ 0.05). RESULTS:The mean (± SD) values of the pharmacokinetic parameters (test vs reference) were Cmax (265.15 ± 49.84 ng/mL vs 246.79 ± 29.30 ng/mL, P < 0.05), Area under the curve (AUC)(0-t) (1033.13 ± 298.74 ng.h/mL vs 952.93 ± 244.07 ng.h/mL, P < 0.05), AUC(0-∞) (1047.61 ± 301.22 ng.h/mL vs 964.21 ± 246.45 ng.h/mL, P < 0.05), and t½(1.92 ± 0.94 h vs 2.05 ± 1.01 h, P < 0.05).The 90% confidence intervals (CI) for the test/reference ratio of mean Cmax, AUC(0-t), and AUC(0-∞) were within the acceptable range of 80.00 to 125.00. The mean times (± SD) to attain maximal plasma concentration (tmax) of lafutidine were 0.95 ± 0.24 h vs 1.01 ± 0.29 h (P < 0.05) for the test and the reference formulations respectively. Both the formulations were well tolerated. CONCLUSION:In summary, this study has demonstrated the bioequivalence of the two formulations of lafutidine 10 mg. Hence it can be concluded that the two formulations can be used interchangeably in clinical settings.© 2010 Baishideng. All rights reserved.Key words: Liquid chromatography/tandem mass spectrometry; Lafutidine; Gastroprotective; Pharmacokinetics; Bioequivalence

Untitled

“…Formation of hydrogen bond between gelatin and tannic acid, as well as the carboxyl groups on the polymeric carrier, produce an integrated matrix, which is shown to be stable after swelling. The gastroretentive tablet can swell up to 22 times its own volume within a 40 min period maintaining its original shape 15 .…”

Preparation and Characterization of Lafutidine as Immediate Release Oral Strip Using Different Type of Water-Soluble Polymer

“…Lafutidine has a receptor binding affinity which is 2-80 times higher than other representative H2-receptor antagonists (e. g. famotidine, ranitidine and cimetidine) [9].…”

“…Lafutidine has been found to significantly increase plasma somatostatin level at (0.3-2) h after administration where somatostatin inhibites gastric acid secretion by acting directly on its receptor on a parietal cell and indirectly by decreasing gastrin from antral G cell [9].…”